Takayasu arteritis and giant cell arteritis: are they a spectrum of the same disease?

International Journal of Rheumatic Diseases

Volumn 22, Issue , 2019, Pages 41-48

  Kermani, Tanaz A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

clinical features; epidemiology; giant cell arteritis; imaging; pathogenesis; Takayasu arteritis; treatment

Indexed keywords

ABATACEPT; GAMMA INTERFERON; GLUCOCORTICOID; HELPER FACTOR; INTERLEUKIN 17; TOCILIZUMAB; IMMUNOSUPPRESSIVE AGENT;

AGE; AORTIC ARCH SYNDROME; CLINICAL ASSESSMENT; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DISEASE ASSOCIATION; GEOGRAPHY; GIANT CELL ARTERITIS; HISTOPATHOLOGY; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; MAGNETIC RESONANCE ANGIOGRAPHY; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; TH1 CELL; TH17 CELL; TREATMENT RESPONSE; ULTRASOUND; ADOLESCENT; ADULT; DIFFERENTIAL DIAGNOSIS; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED; ONSET AGE; PHENOTYPE; PREDICTIVE VALUE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGE OF ONSET; DIAGNOSIS, DIFFERENTIAL; FEMALE; GIANT CELL ARTERITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PHENOTYPE; PREDICTIVE VALUE OF TESTS; TAKAYASU ARTERITIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85044970659     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.13288     Document Type: Review

References (65)

1. Arend WP, Michel BA, Bloch DA et al. (1990) The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 33, 1129–34.
2. Hunder GG, Bloch DA, Michel BA et al. (1990) The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33, 1122–8.
3. Maksimowicz-McKinnon K, Clark TM, Hoffman GS (2009) Takayasu arteritis and giant cell arteritis: a spectrum within the same disease? Medicine (Baltimore) 88, 221–6.
4. Michel BA, Arend WP, Hunder GG (1996) Clinical differentiation between giant cell (temporal) arteritis and Takayasu's arteritis. J Rheumatol 23 (1), 106–11.
5. Stone JR, Bruneval P, Angelini A et al. (2015) Consensus statement on surgical pathology of the aorta from the Society for Cardiovascular Pathology and the Association for European Cardiovascular Pathology: I. Inflammatory diseases. Cardiovasc Pathol 24, 267–78.
6. Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM (2010) Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 121, 906–15.
7. Saadoun D, Garrido M, Comarmond C et al. (2015) Th1 and Th17 cytokines drive inflammation in Takayasu arteritis. Arthritis Rheumatol 67, 1353–60.
8. Furuta S, Cousins C, Chaudhry A, Jayne D (2015) Clinical features and radiological findings in large vessel vasculitis: are Takayasu arteritis and giant cell arteritis 2 different diseases or a single entity? J Rheumatol 42, 300–8.
9. Grayson PC, Maksimowicz-McKinnon K, Clark TM et al. (2012) Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis. Ann Rheum Dis 71, 1329–34.
10. Kermani TA, Crowson CS, Muratore F, Schmidt J, Matteson EL, Warrington KJ (2015) Extra-cranial giant cell arteritis and Takayasu arteritis: how similar are they? Semin Arthritis Rheum 44, 724–8.
11. Yoshida M, Watanabe R, Ishii T et al. (2016) Retrospective analysis of 95 patients with large vessel vasculitis: a single center experience. Int J Rheum Dis 19 (1), 87–94.
12. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ et al. (2009) Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 61, 1454–61.
13. Japanese Circulation Society Joint Working Group (2011) Guideline for management of vasculitis syndrome (JCS 2008). Japanese Circulation Society. Circ J 75, 474–503.
14. Watanabe Y, Miyata T, Tanemoto K (2015) Current clinical features of new patients with takayasu arteritis observed from cross-country research in Japan: age and sex specificity. Circulation 132, 1701–9.
15. Carmona FD, Martin J, Gonzalez-Gay MA (2015) Genetics of vasculitis. Curr Opin Rheumatol 27 (1), 10–7.
16. Arnaud L, Haroche J, Mathian A, Gorochov G, Amoura Z (2011) Pathogenesis of Takayasu's arteritis: a 2011 update. Autoimmun Rev 11 (1), 61–7.
17. Grayson PC, Tomasson G, Cuthbertson D et al. (2012) Association of vascular physical examination findings and arteriographic lesions in large vessel vasculitis. J Rheumatol 39, 303–9.
18. Hoffman GS, Cid MC, Rendt-Zagar KE et al. (2007) Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 146, 621–30.
19. Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P (2004) Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 50, 2296–304.
20. Langford CA, Cuthbertson D, Ytterberg SR et al. (2017) A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol 69, 837–45.
21. Langford CA, Cuthbertson D, Ytterberg SR et al. (2017) A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of Takayasu arteritis. Arthritis Rheumatol 69, 846–53.
22. Jennette JC, Falk RJ, Bacon PA et al. (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 (1), 1–11.
23. Muratore F, Kermani TA, Crowson CS et al. (2015) Large-vessel giant cell arteritis: a cohort study. Rheumatology (Oxford) 54, 463–70.
24. Stone JH, Tuckwell K, Dimonaco S et al. (2017) Trial of tocilizumab in giant-cell arteritis. N Engl J Med 377, 317–28.
25. Craven A, Robson J, Ponte C et al. (2013) ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS). Clin Exp Nephrol 17, 619–21.
26. Birlik M, Kucukyavas Y, Aksu K et al. (2016) Epidemiology of Takayasu's arteritis in Turkey. Clin Exp Rheumatol 34 (3 Suppl. 97), S33–9.
27. Watts R, Al-Taiar A, Mooney J, Scott D, Macgregor A (2009) The epidemiology of Takayasu arteritis in the UK. Rheumatology (Oxford) 48, 1008–11.
28. Sharma A, Sagar V, Prakash M et al. (2015) Giant cell arteritis in India: report from a tertiary care center along with total published experience from India. Neurol India 63, 681–6.
29. Carmona FD, Coit P, Saruhan-Direskeneli G et al. (2017) Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy. Sci Rep 7, 43953.
30. Weyand CM, Goronzy JJ (2013) Immune mechanisms in medium and large-vessel vasculitis. Nat Rev Rheumatol 9, 731–40.
31. Agard C, Barrier JH, Dupas B et al. (2008) Aortic involvement in recent-onset giant cell (temporal) arteritis: a case-control prospective study using helical aortic computed tomodensitometric scan. Arthritis Rheum 59, 670–6.
32. Aschwanden M, Kesten F, Stern M et al. (2010) Vascular involvement in patients with giant cell arteritis determined by duplex sonography of 2x11 arterial regions. Ann Rheum Dis 69, 1356–9.
33. Blockmans D, de Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H (2006) Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum 55 (1), 131–7.
34. Diamantopoulos AP, Haugeberg G, Hetland H, Soldal DM, Bie R, Myklebust G (2014) Diagnostic value of color Doppler ultrasonography of temporal arteries and large vessels in giant cell arteritis: a consecutive case series. Arthritis Care Res (Hoboken) 66 (1), 113–9.
35. Ghinoi A, Pipitone N, Nicolini A et al. (2012) Large-vessel involvement in recent-onset giant cell arteritis: a case-control colour-Doppler sonography study. Rheumatology (Oxford) 51, 730–4.
36. Prieto-Gonzalez S, Arguis P, Garcia-Martinez A et al. (2012) Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography. Ann Rheum Dis 71, 1170–6.
37. Prieto-Gonzalez S, Depetris M, Garcia-Martinez A et al. (2014) Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: a prospective, case-control study. Ann Rheum Dis 73, 1388–92.
38. Schmidt WA, Natusch A, Moller DE, Vorpahl K, Gromnica-Ihle E (2002) Involvement of peripheral arteries in giant cell arteritis: a color Doppler sonography study. Clin Exp Rheumatol 20, 309–18.
39. Schmidt WA, Seifert A, Gromnica-Ihle E, Krause A, Natusch A (2008) Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. Rheumatology (Oxford) 47 (1), 96–101.
40. Brack A, Martinez-Taboada V, Stanson A, Goronzy JJ, Weyand CM (1999) Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum 42, 311–7.
41. Arnaud L, Haroche J, Limal N et al. (2010) Takayasu arteritis in France: a single-center retrospective study of 82 cases comparing white, North African, and black patients. Medicine (Baltimore) 89 (1), 1–17.
42. Kerr GS, Hallahan CW, Giordano J et al. (1994) Takayasu arteritis. Ann Intern Med 120, 919–29.
43. Ohigashi H, Haraguchi G, Konishi M et al. (2012) Improved prognosis of Takayasu arteritis over the past decade–comprehensive analysis of 106 patients. Circ J 76, 1004–11.
44. Vanoli M, Daina E, Salvarani C et al. (2005) Takayasu's arteritis: a study of 104 Italian patients. Arthritis Rheum 53 (1), 100–7.
45. Schmidt J, Kermani TA, Bacani AK et al. (2013) Diagnostic features, treatment, and outcomes of Takayasu arteritis in a US cohort of 126 patients. Mayo Clin Proc 88, 822–30.
46. Direskeneli H, Aydin SZ, Kermani TA et al. (2011) Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda. J Rheumatol 38, 1471–9.
47. Muratore F, Pipitone N, Salvarani C, Schmidt WA (2016) Imaging of vasculitis: state of the art. Best Pract Res Clin Rheumatol 30, 688–706.
48. Comarmond C, Plaisier E, Dahan K et al. (2012) Anti TNF-alpha in refractory Takayasu's arteritis: cases series and review of the literature. Autoimmun Rev 11, 678–84.
49. Gudbrandsson B, Molberg O, Palm O (2017) TNF inhibitors appear to inhibit disease progression and improve outcome in Takayasu arteritis; an observational, population-based time trend study. Arthritis Res Ther 19 (1), 99.
50. Mekinian A, Comarmond C, Resche-Rigon M et al. (2015) Efficacy of biological-targeted treatments in Takayasu arteritis: multicenter, retrospective study of 49 patients. Circulation 132, 1693–700.
51. Molloy ES, Langford CA, Clark TM, Gota CE, Hoffman GS (2008) Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 67, 1567–9.
52. Schmidt J, Kermani TA, Bacani AK, Crowson CS, Matteson EL, Warrington KJ (2012) Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup. Arthritis Care Res (Hoboken) 64, 1079–83.
53. Martinez-Taboada VM, Rodriguez-Valverde V, Carreno L et al. (2008) A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 67, 625–30.
54. Seror R, Baron G, Hachulla E et al. (2014) Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis 73, 2074–81.
55. Garcia-Martinez A, Hernandez-Rodriguez J, Espigol-Frigole G et al. (2010) Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis. Arthritis Care Res (Hoboken) 62, 835–41.
56. Hernandez-Rodriguez J, Segarra M, Vilardell C et al. (2004) Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford) 43, 294–301.
57. Visvanathan S, Rahman MU, Hoffman GS et al. (2011) Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis – a prospective longitudinal study. Rheumatology (Oxford) 50, 2061–70.
58. Nakaoka Y, Isobe M, Takei S et al. (2018) Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis 77, 348–54.
59. Villiger PM, Adler S, Kuchen S et al. (2016) Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 387, 1921–7.
60. Kermani TA, Cuthbertson D, Carette S et al. (2016) The Birmingham Vasculitis Activity score as a measure of disease activity in patients with giant cell arteritis. J Rheumatol 43, 1078–84.
61. Misra R, Danda D, Rajappa SM et al. (2013) Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). Rheumatology (Oxford) 52, 1795–801.
62. Alibaz-Oner F, Aydin SZ, Akar S et al. (2015) Assessment of patients with Takayasu arteritis in routine practice with Indian Takayasu Clinical Activity Score. J Rheumatol 42, 1443–7.
63. Sreih AG, Alibaz-Oner F, Kermani TA et al. (2017) Development of a core set of outcome measures for large-vessel vasculitis: report from OMERACT 2016. J Rheumatol 44, 1933–7.
64. Aydin SZ, Direskeneli H, Merkel PA, International Delphi on Disease Activity Assessment in Large-vessel Vasculitis (2017) Assessment of disease activity in large-vessel vasculitis: results of an International Delphi Exercise. J Rheumatol 44, 1928–32.
65. Maksimowicz-McKinnon K, Clark TM, Hoffman GS (2007) Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum 56, 1000–9.